Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cytek Biosciences Q1 EPS $(0.09) Misses $(0.04) Estimate, Sales $51.93M Beat $42.66M Estimate

Author: Benzinga Newsdesk | May 08, 2025 03:26pm
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 125 percent. This is a 80 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $51.93 million which beat the analyst consensus estimate of $42.66 million by 21.72 percent. This is a 15.76 percent increase over sales of $44.86 million the same period last year.

Posted In: CTKB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist